Emerging Therapeutic Segments in the European Biopharmaceutical Markets

Emerging Therapeutic Segments in the European Biopharmaceutical Markets published by Frost & Sullivan in August, 2009. This report price starts from US $ 6500.

Introduction

Abstract

The research services provides an analysis of the European markets for emerging therapeutic areas such as antisense therapy, gene therapy and cell therapy. The research services segments the market based on the drug classes. The research analyses the challenges faced by the biopharmaceutical industry and the potential uses for the emerging therapeutic areas. The research also provides market sizes for the total biopharmaceutical markets and the market for emerging therapeutic areas.

Table of Contents

1. EXECUTIVE SUMMARY

• Introduction
  • 1. Summary

2. MARKET OVERVIEW

3. MARKET ANALYSIS

• Market Introduction
  • 1. Introduction
  • 2. Measurements
  • 3. Main Classes of Biopharmaceuticals
  • 4. Recent Product Approvals in Europe
  • 5. Competitive Structure
• Research Scope and Methodology
  • 1. Scope and Segmentation
  • 2. Research Methodology
• Market Trends
  • 1. Industry Challenges
  • 2. Market Drivers
  • 3. Market Restraints
• Pipeline Analysis
  • 1. Antisense Therapies
  • 2. Gene Therapies
  • 3. Cell Therapies

4. REVENUE ANALYSIS

• Total Market Forecasts
  • 1. Revenue Forecasts
• Segment Analysis
  • 1. Segment Forecasts
  • 2. Antisense Therapies
  • 3. Gene Therapies
  • 4. Cell Therapies

5. DECISION SUPPORT DATABASES

• Databases
  • 1. Cancer Cases
  • 2. Prevalence of Arthritis
  • 3. Prevalence of Multiple Sclerosis
  • 4. Prevalence of Cardiovascular Diseases
  • 5. Pharma Government Biotech R&D Investment

Related Reports